Oorsprong van het eerstegraads netwerk van Nicholas O'Leary
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Ncardia Holding SA
Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015.
6
| Private Company | Biotechnology | 6 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Nicholas O'Leary via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Ncardia SA
Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Miscellaneous Commercial Services | Director/Board Member Founder | |
A Q Invest SRL | Corporate Officer/Principal | ||
Bio-Sourcing SA
Bio-Sourcing SA BiotechnologyHealth Technology Bio-Sourcing SA develops and markets biological drugs for veterinary use. The firm focuses on farm animal health and companion animal health. The company was founded by Bertrand Mérot in June 2011 and is headquartered in Liege, Belgium. | Biotechnology | Director/Board Member | |
Université Catholique de Louvain | College/University | Graduate Degree | |
ACTICOR BIOTECH SAS | Biotechnology | Director/Board Member | |
Solvay Business School of Economics & Management | College/University | Undergraduate Degree | |
AQ Partners SRL | Corporate Officer/Principal | ||
Vesalius Biocapital II Partners SARL | Founder | ||
Cellistic
Cellistic BiotechnologyHealth Technology Part of Ncardia SA, Cellistic is a subsidiary that specializes in the process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The Belgian company's focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development make it an ideal partner for innovative cell therapy developers to commercialize novel advanced therapies. The company was founded by Stefan Braam, and Gustavo Mahler has been the CEO of the company since 2023. | Biotechnology | Founder | |
MaSTherCell SA
MaSTherCell SA BiotechnologyHealth Technology MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium. | Biotechnology | Chief Executive Officer | |
ORGENESIS INC. | Biotechnology | Corporate Officer/Principal | |
University of Liege | College/University | Doctorate Degree | |
Catalent MSTC, Inc.
Catalent MSTC, Inc. Medical SpecialtiesHealth Technology Catalent MSTC, Inc. provides full service contract development and manufacturing services (CDMO) for cell therapy companies. It offers process and assay development, quality management, and cGMP cell therapy manufacturing services. The company was incorporated on December 27, 2017 and is headquartered in Dover, DE. | Medical Specialties | President | |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | Biotechnology | Chief Executive Officer | |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Newton Biocapital Partners SRL
Newton Biocapital Partners SRL Investment ManagersFinance Newton Biocapital Partners SPRL is an Independent Venture Capital firm founded in 2017 by Alain Parthoens. Newton Biocapital Partners SPRL is headquartered in Woluwe-Saint-Pierre. | Investment Managers | Founder | |
Epics Therapeutics SA
Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Miscellaneous Commercial Services | Founder | |
CropDesign NV
CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member | |
Biotechnological Enzymatic Catalyse NV
Biotechnological Enzymatic Catalyse NV Food: Major DiversifiedConsumer Non-Durables Biotechnological Enzymatic Catalyse NV develops, produces and commercializes enzymatic systems for food preservation. It engages in the research, development and manufacturing of antimicrobial products for food safety. The firm's solutions are designed for use in the following: dairy products, fruit and vegetable juices, sauces and dressings and liquid egg products. The company was founded in 1992 and is headquartered in Ghent, Belgium. | Food: Major Diversified | Director/Board Member | |
TIGENIX NV | Medical Specialties | Director/Board Member | |
Maize Technologies International GmbH | Director/Board Member | ||
MDXHEALTH SA | Medical Specialties | Director/Board Member | |
The Belgian Venture Capital & Private Equity Association
The Belgian Venture Capital & Private Equity Association Miscellaneous Commercial ServicesCommercial Services The Belgian Venture Capital & Private Equity Association provides equity capital to enterprises not quoted on a stock market. The firm develops new products and technologies to expand working capital, to make acquisitions or to strengthen a company’s balance sheet. The company was founded in 1986 and is headquartered in Brussels, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Tibotec Virco NV
Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
AQ Invest BV | Corporate Officer/Principal | ||
Université Libre de Bruxelles | College/University | Graduate Degree | |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Miscellaneous Commercial Services | Director/Board Member | |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member | |
Vesalius Biocapital Partners SARL
Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg. | Investment Managers | Private Equity Investor | |
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Director/Board Member | |
VOLUNTIS S.A. | Packaged Software | Director/Board Member | |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Exothera SA
Exothera SA Chemicals: SpecialtyProcess Industries Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere. | Chemicals: Specialty | Director/Board Member |
Statistieken
Internationaal
België | 26 |
Verenigde Staten | 4 |
Nederland | 3 |
Frankrijk | 3 |
Luxemburg | 3 |
Sectoraal
Health Technology | 16 |
Commercial Services | 7 |
Consumer Services | 5 |
Technology Services | 3 |
Finance | 3 |
Operationeel
Director/Board Member | 30 |
Founder | 7 |
Corporate Officer/Principal | 6 |
Chief Executive Officer | 6 |
Undergraduate Degree | 3 |
Sterkste connecties
Insiders | |
---|---|
Alain Parthoens | 29 |
Denis Bedoret | 7 |
Stefan Braam | 4 |
Jason Conner | 2 |
Christine Franssen | 1 |
Geoffrey Glass | 1 |
- Beurs
- Insiders
- Nicholas O'Leary
- Bedrijfsconnecties